List of SBIR/STTR awards granted to Cytex Therapeutics
Name | Description | SBIR/STTR Award Recipient | Government Agency | Government Branch | Award Type | Contract Number (US Government) | Award Phase | Award Amount (USD) | Date Awarded | Official Website | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
A SBIR Phase II contract was awarded to Cytex Therapeutics in September, 2017 for $1,413,364.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44AG059310-01 | Phase II | 1,413,364 | September 15, 2017 | |||||||
A SBIR Phase II contract was awarded to Cytex Therapeutics in June, 2020 for $829,606.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44AR077467-01 | Phase II | 829,606 | June 1, 2020 | |||||||
A STTR Phase I contract was awarded to Cytex Therapeutics in September, 2019 for $225,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | STTR | 1R41AR074837-01A1 | Phase I | 225,000 | September 9, 2019 | |||||||
A SBIR Phase I contract was awarded to Cytex Therapeutics in September, 2018 for $225,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AR073716-01 | Phase I | 225,000 | September 18, 2018 | |||||||
A SBIR Phase II contract was awarded to Cytex Therapeutics in September, 2022 for $400,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 2SB1AR066439-04A1 | Phase II | 400,000 | September 21, 2022 | |||||||
A STTR Phase I contract was awarded to Cytex Therapeutics in September, 2015 for $190,720.0 USD from the U.S. Department of Health & Human Services. | STTR | 1R42AR066439-01A1 | Phase I | 190,720 | September 8, 2015 | |||||||
A SBIR Phase II contract was awarded to Cytex Therapeutics in September, 2017 for $1,159,905.0 USD from the U.S. Department of Health & Human Services. | SBIR | 9SB1AG059313-04 | Phase II | 1,159,905 | September 15, 2017 | |||||||
A SBIR Phase II contract was awarded to Cytex Therapeutics in September, 2017 for $1,199,997.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2SB1AR061916-04 | Phase II | 1,199,997 | September 1, 2017 | |||||||
A SBIR Phase II contract was awarded to Cytex Therapeutics in September, 2016 for $187,590.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2SB1AR055414-04 | Phase II | 187,590 | September 19, 2016 | |||||||
A STTR Phase II contract was awarded to Cytex Therapeutics in April, 2017 for $1,406,959.0 USD from the U.S. Department of Health & Human Services. | STTR | 4R42AR066439-02 | Phase II | 1,406,959 | April 1, 2017 | |||||||
A SBIR Phase I contract was awarded to Cytex Therapeutics in September, 2017 for $225,000.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AR072166-01 | Phase I | 225,000 | September 1, 2017 | |||||||
A SBIR Phase II contract was awarded to Cytex Therapeutics in September, 2015 for $1,327,689.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44AR061916-02 | Phase II | 1,327,689 | September 1, 2015 | |||||||
A SBIR Phase I contract was awarded to Cytex Therapeutics in July, 2013 for $149,993.0 USD from the National Science Foundation. | SBIR | 1315189 | Phase I | 149,993 | July 1, 2013 | |||||||
A SBIR Phase II contract was awarded to Cytex Therapeutics in September, 2020 for $1,498,253.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44AG059310-03 | Phase II | 1,498,253 | September 30, 2020 | |||||||
A STTR Phase I contract was awarded to Cytex Therapeutics for $299,744.0 USD from the U.S. Department of Health & Human Services. | STTR | 1R41AG047014-01 | Phase I | 299,744 | ||||||||
A STTR Phase I contract was awarded to Cytex Therapeutics for $261,996.0 USD from the U.S. Department of Health & Human Services. | STTR | 1R41AR055042-01A1 | Phase I | 261,996 | ||||||||
A STTR Phase II contract was awarded to Cytex Therapeutics for $1,303,192.0 USD from the U.S. Department of Health & Human Services. | STTR | 2R42AR055042-02 | Phase II | 1,303,192 | ||||||||
A SBIR Phase I contract was awarded to Cytex Therapeutics for $198,625.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AR057600-01 | Phase I | 198,625 | ||||||||
A STTR Phase I contract was awarded to Cytex Therapeutics for $236,632.0 USD from the U.S. Department of Health & Human Services. | STTR | 1R41AR055414-01 | Phase I | 236,632 | ||||||||
A STTR Phase I contract was awarded to Cytex Therapeutics for $299,664.0 USD from the U.S. Department of Health & Human Services. | STTR | 1R41AG047621-01A1 | Phase I | 299,664 | ||||||||
A STTR Phase II contract was awarded to Cytex Therapeutics for $1,139,180.0 USD from the U.S. Department of Health & Human Services. | STTR | 2R42AR055414-02 | Phase II | 1,139,180 | ||||||||
A SBIR Phase I contract was awarded to Cytex Therapeutics for $299,327.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AR061916-01A1 | Phase I | 299,327 | ||||||||
A STTR Phase I contract was awarded to Cytex Therapeutics in September, 2023 for $282,265.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | STTR | 1R41AR083778-01 | Phase I | 282,265 | September 18, 2023 |
